THE USE OF PATIENT REPORTED OUTCOMES (PROS) BY THE PHARMACEUTICAL INDUSTRY IN JAPAN - A BRIEF REVIEW OF PMDA DATA IN COMPARISON WITH FDA AND EMA-APROVED LABEL CLAIMS

被引：0
|
作者：
Ledesma, D. A. [1 ]
Tanaka, E. [1 ]
Adachi, K. [1 ]
Rossi, B. [2 ]
机构：
[1] Bayer Yakuhin Ltd, Tokyo, Japan
[2] Bayer Yakuhin Ltd, Osaka, Japan
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.1605
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIH75
引用
收藏
页码：A517 / A517
页数：1
相关论文
共 4 条
  • [1] PATIENT-REPORTED OUTCOMES CLAIMS IN ACROMEGALY: A REVIEW OF THE LABELS OF PRODUCTS APPROVED BY THE FDA AND THE EMA
    Perret, C.
    Perrier, L.
    Acquadro, C.
    VALUE IN HEALTH, 2016, 19 (03) : A208 - A208
  • [2] Patient-reported outcomes (PROs) Used to support claims in myeloproliferative neoplasms (MPNs): a review of the labels of products approved by the EMA
    Perret, Cecile
    Perrier, Laure-Lou
    Acquadro, Catherine
    QUALITY OF LIFE RESEARCH, 2016, 25 : 120 - 121
  • [3] Impact of open-label design on patient-reported outcomes (PROs) data in randomized clinical trials of immuno-oncology (IO) agents in patients with advanced or metastatic cancer: A 10-year systematic literature review (SLR)
    Anota, A.
    Pozet, A.
    Lefevre, C.
    Lemasson, H.
    Cotte, F-E.
    Guerzider, S.
    Mouillet, G.
    Eberst, G.
    Charton, E.
    Westeel, V.
    ANNALS OF ONCOLOGY, 2019, 30
  • [4] Impact of open-label design on patient-reported outcomes (PROs) data in randomized clinical trials of immuno-oncology (IO) agents in patients with advanced or metastatic cancer: a 10-year systematic literature review (SLR)
    Anota, Amelie
    Pozet, Astrid
    Lemasson, Herve
    Cotte, Francois-Emery
    Guerzider, Stephane
    Mouillet, Guillaume
    Eberst, Guillaume
    Charton, Emilie
    Westeel, Virginie
    QUALITY OF LIFE RESEARCH, 2020, 29 (SUPPL 1) : S156 - S156
1